Bacillus Calmette–Guérin and anti-PD-L1 combination therapy boosts immune response against bladder cancer

Yonghua Wang1
Jing Liu2
Xuecheng Yang1
Yanan Liu1
Yong Liu1
Yanjian Li1
Lijiang Sun1
Xiaokun Yang1
Haitao Niu1

1Department of Urology, 2Department of Pediatrics, The Affiliated Hospital of Qingdao University, Qingdao 266000, People's Republic of China

Background: Programmed death-ligand 1 (PD-L1) is a critical immune checkpoint molecule which promotes immunosuppression by binding to PD-1 on T-cells in tumor immunity. We have previously identified that activation of toll like receptor 4 (TLR-4), which serves an important role in the induction of antitumor immune response during Bacillus Calmette–Guérin (BCG) immunotherapy, could upregulate PD-L1 expression in bladder cancer (BCa) cells through the classical mitogen-activated protein kinase (MAPK) pathway and subsequently weaken the cytotoxicity of cytotoxic T lymphocyte (CTL). It is, therefore, necessary to investigate the possible potential relationship between PD-L1 expression and BCG immunotherapy.

Materials and methods: In this study we investigated the effects of BCG treatment on PD-L1 expression in BCa cells and also evaluated the efficacy of BCG and anti-PD-L1 combination therapy in immunocompetent orthotopic rat BCa models.

Results: We found that PD-L1 expression was obviously upregulated in BCa cells in response to BCG treatment both in vitro and in vivo. Moreover, BCG and anti-PD-L1 combination treatment activated a potent antitumor immune response with the increase in the number and activity of tumor-infiltrating CD8+ T cells, as well as the reduction in myeloid-derived suppressor cells (MDSCs), and eventually elicits prominent tumor growth inhibition and prolonged survival, and was found to be much more effective than either agent alone.

Conclusion: These findings highlight the adaptive dynamic regulation of PD-L1 in response to BCG immunotherapy and suggest that combination of BCG immunotherapy with PD-L1 blockade may be an effective antitumor strategy for improving treatment outcomes of BCa.

Keywords: BCG, PD-L1, bladder cancer, immunotherapy, combination therapy

Introduction

Bladder cancer (BCa) is the fourth most common cancer in men in the USA, showing high morbidity and mortality rates.1 Approximately 70% of newly diagnosed BCa presents as non-muscle invasive bladder cancer (NMIBC). Although transurethral resection of bladder tumor (TURBT) is the primary treatment for NMIBC, recurrence rate for TURBT alone can be as high as 70%, with up to 30% progressing to muscle invasive disease.2 Intravesical Bacillus Calmette–Guérin (BCG) is recommended as adjuvant therapy to reduce the risk of tumor recurrence and possibly decrease progression in intermediate and high risk NMIBC. While BCG has obtained successful responses against NMIBC, approximately 30%-40% of patients fail this therapy with recurrence or progression.3 The precise mechanism of BCG failure is not clear, but current studies indicate that immune resistance or immune evasion may be critical factors in the mechanisms of BCG failure.4,5
Programmed death-ligand 1 (PD-L1), also known as B7-H1, is a newly discovered T-cell costimulatory molecule and immune checkpoint molecule in tumor immunity. The interaction between PD-L1 and its receptor programmed death 1 (PD-1) can inhibit immune responses by inducing T-cell apoptosis, impairing cytokine production, and diminishing the cytotoxicity of activated T cells, and may endow tumors with a mechanism to escape host immune destruction.\(^4\) The upregulation of PD-L1 expression has been reported to be associated with poor prognosis and resistance to anticancer therapies in many malignancies, including BCa.\(^7\)–\(^10\) Moreover, blockade of the PD-L1/PD-1 axis was shown to induce a potent antitumor immune response in preclinical mouse models as well as in the clinic.\(^11\)–\(^13\)

Our previous studies found that activation of toll like receptor 4 (TLR-4) signaling in BCa cells could upregulate PD-L1 expression through the MAPK pathway and subsequently weaken the cytotoxicity of cytotoxic T lymphocyte (CTL) against BCa cells.\(^14\) BCG is a potent activator of TLR-4-dependent signaling and TLR-4 has also been demonstrated to serve an important role in the induction of BCG-induced antitumor immunity during intravesical BCG therapy.\(^15\) Thus, we hypothesized that BCG induces a local inflammatory response that could enhance the infiltration of tumor-specific T cells and simultaneously induce PD-L1 expression in the tumor microenvironment. The accumulation of PD-L1-expressing cells in bladder tissues may gradually impair host cell-mediated immunity, limit and even abrogate the effectiveness of BCG immunotherapy. Moreover, the concept of BCG-induced PD-L1 expression and subsequent blockade might broaden the application of PD-L1/PD-1 axis inhibitors and prove to be a potent anticancer therapy when combined with BCG immunotherapy.

In this study we first investigated the effects of BCG treatment on PD-L1 expression in BCa cell line and orthotopic rat BCa models. Moreover, we further evaluated whether the combination of BCG immunotherapy with PD-L1 blockade could enhance and optimize the antitumor immunity in BCa.

**Materials and methods**

**Cell culture**

Human BCa cell line T24 cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cells were cultured in RPMI 1640 media (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (Thermo Fisher Scientific), 100 U/mL penicillin (Sigma-Aldrich, St Louis, MO, USA) and 100 \(\mu\)g/mL streptomycin (Sigma-Aldrich) at 37°C in a humidified atmosphere containing 5% \(\text{CO}_2\) and 95% air. Cells in the logarithmic phase of growth were used for further experiments.

**Establishment of orthotopic rat BCa model**

Female Sprague-Dawley rats (6–8 weeks of age, weighing 200–250 g) were obtained from the Experimental Animal Center of Shanghai Jiaotong University (Shanghai, China). The ethics committees from Qingdao University Affiliated Hospital have approved this animal study, and the approval was obtained prior to the commencement of the study. All animal studies were carried out following the guidelines and regulations of the Animal Care and Use Committees of Qingdao University Affiliated Hospital. All rats were housed in microisolator cages under specific pathogen-free conditions on a 12 h light–dark cycle. Rat BCa models were constructed by intravesical instillation of N-methyl-N-nitrosourea (MNU, Sigma-Aldrich) at 2 mg/rat every other week for a total of four doses. At the end of the 8th week, all rats received abdominal computed tomography examination to observe the tumorigenic situation. Three rats were sacrificed and their bladders were harvested for histological study.

**BCG treatment**

The cultured T24 cells were pre-treated with BCG (1.0×10\(^6\) CFU/mg, REBIO, Shanghai, China) at various concentrations (bacterium/cell ratio of 0, 2.5:1, 5:1, 10:1 and 20:1) and incubation times (0 h, 2 h, 4 h, 6 h, 8 h and 10 h). Orthotopic tumor-bearing rats received intravesical instillation with BCG (2.5 mg/mL, 0.2 mL), or epirubicin (5 mg/mL, 0.2 mL), or gemcitabine (20 mg/mL, 0.2 mL), or normal saline (0.2 mL) every week for four doses.

**Blockade of PD-L1 with antibodies**

For the PD-L1 blockade experiment, 200 \(\mu\)g anti-PD-L1 (clone 10F.9G2, Bio-XCell, West Lebanon, NH, USA) was administered by intraperitoneal injection to orthotopic tumor-bearing rats every 4 days for a total of seven times. For the combination of BCG with anti-PD-L1 experiment, antibody treatments were started from the day of intravesical BCG instillation.

**Flow cytometry analysis**

The expressions of PD-L1 in T24 cells and tumor tissues of orthotopic rat BCa models were evaluated by flow cytometry. Phycocerythrin-labeled PD-L1 antibody (clone MIH1/MIH5, eBioscience, San Diego, CA, USA) or isotype-matched
control antibody was added at a concentration of 1 μg per 1×10^6 cells per 100 μL and cells were incubated for 30 min at 4°C. To detect CD8^+ T cells and myeloid-derived suppressor cells (MDSCs) in tumor tissues, tumor infiltrating lymphocytes (TILs) were isolated from the single cell suspension by Ficoll-Hypaque density gradient centrifugation and then stained with anti-CD8 (clone 5H10), anti-CD11b (clone M1/70) and anti-Gr1 (clone Ly-6G/Ly-6C) (eBioscience). In addition, anti-IFN-γ (clone XMG1.2), anti-granzyme B (clone NGZB) and anti-TNF-α (clone MP6-XT22) (eBioscience) were used to detect IFN-γ, granzyme B and TNF-α secretion level in CD8^+ T cells. Flow cytometric analysis was performed with a FACSCalibur (BD Biosciences, San Jose, CA, USA) and data were analyzed using CellQuest software (BD Biosciences).

**Western blot analysis**

Total proteins from tumor tissues were separated on polyacrylamide gel, transferred onto nitrocellulose membrane and incubated with anti-mouse PD-L1 antibody (clone TY25, Santa Cruz Biotechnology, Santa Cruz, CA, USA) overnight at 4°C. Membranes were then washed three times in washing buffer and incubated with anti-rabbit IgG conjugated to peroxidase for 1 h at room temperature. Immunoreactivity was determined by chemiluminescence according to manufacturer instructions.

**Enzyme linked immunosorbent assay (ELISA)**

Serum IFN-γ level was tested by ELISA kits (R&D Systems, Minneapolis, MN, USA) following the manufacturer’s instructions.

**Immunohistochemistry staining**

Animal tumors were sampled and embedded in paraffin. The sections were mounted on superfrost glass slides, paraffinized, rehydrated in a graded ethanol series, and then subjected to microwave antigen retrieval. Endogenous peroxidase activity was blocked by using 3% hydrogen peroxide. Sections were incubated overnight at room temperature with granzyme B antibody (catalog ab4059, Abcam, Cambridge, UK, 1:200 dilution). Staining was revealed by peroxidase/diaminobenzidine reaction. Granzyme B stained cells were then counted and were reported in relation to the total number of cells in the tumor section.

**Statistical analysis**

Data were analyzed using Prism 6.0 software (GraphPad Software, San Diego, CA, USA). Experiments were repeated two or three times. Data are represented as the mean ± standard error and the P-values were assessed by either Student’s t-test or analysis of variance (ANOVA). A P-value <0.05 was considered statistically significant.

**Results**

**PD-L1 expression is upregulated in T24 cells in response to BCG treatment**

First, we investigated the effect of BCG treatment on PD-L1 expression in human BCa cell line T24 cells. As shown in Figure 1A, PD-L1 protein was constitutively expressed in T24 cells and was further upregulated by BCG in a concentration-dependent manner; the increases reached a peak level at a bacterium/cell ratio of 10:1. In order to determine the time course of PD-L1 protein expression in response to BCG treatment, we treated T24 cells with BCG.
(bacterium/cell ratio of 10:1) for the indicated times. Flow cytometry analysis indicated that the maximal induction of PD-L1 protein occurred at 4 h and then slightly decreased at 6, 8 and 10 h (Figure 1B). These results show that BCG treatment can induce the upregulation of PD-L1 expression in BCa cells in vitro.

Increased PD-L1 expression in tumor tissue following intravesical BCG instillation

Current animal models of BCa include chemically induced orthotopic models, xenogeneic/syngeneic transplanted models and transgenic models. To better investigate the effects of intravesical BCG immunotherapy on PD-L1 expression in vivo and exclude immunological interference factors, we established MNU-induced orthotopic rat BCa models which exhibit good tumor take, survival time, and immunocompetence. MNU-induced orthotopic rat BCa models were then treated with intravesical BCG instillation every week for four doses. Interestingly, we found that surface and total PD-L1 protein expressions were obviously increased in the BCG treatment group following intravesical BCG instillation by flow cytometry (Figure 2A) and Western blot (Figure 2B), respectively. In order to demonstrate that the increase in PD-L1 was not simply an effect of general treatment but unique to BCG treatment, normal saline and two other common intravesical chemotherapy agents were also used in our study as controls. Epirubicin, an anthracycline antibiotic, is a cell cycle non-specific agent that exerts antitumor effects by affecting DNA synthesis. Gemcitabine, which is a cell cycle specific agent, is an antimetabolite pyrimidine base analog that exhibits antitumor activity by inhibiting ribonucleotide reductase, incorporating into DNA and causing S phase arrest. However, no significant differences in PD-L1 protein expression were observed in the normal saline treatment group, epirubicin treatment group and gemcitabine treatment group. These results demonstrate that the upregulation and accumulation of PD-L1 does exist in the tumor microenvironment following intravesical BCG instillation in vivo.

BCG and anti-PD-L1 combination therapy enhances antitumor effects in BCa

As upregulation of PD-L1 has been demonstrated in BCa cells following BCG treatment both in vitro and in vivo, we hypothesized that blockade of PD-L1 could enhance BCG immunotherapy by alleviating the inhibitory action of PD-L1 on T cells and uncover the full cytotoxic potential of host immunity against the tumor. To test this hypothesis, MNU-induced orthotopic rat BCa models were treated with
intravesical BCG instillation alone, anti-PD-L1 alone, or BCG plus anti-PD-L1 (Figure 3A). The results showed that with a combination treatment of BCG and anti-PD-L1 there was a significant slow-down in tumor weight as compared to single treatments or the control group (control 1.30±0.41 g; BCG 0.86±0.42 g; anti-PD-L1 0.80±0.34 g; combination 0.35±0.14 g) (Figure 3B). Moreover, survival curves showed that combination treatment of BCG and anti-PD-L1 did significantly prolong survival over single treatments or the control group (Figure 3C). Thus, these results demonstrated that the combination therapy was superior to monotherapy with either agent in exerting an antitumor response.

BCG and anti-PD-L1 combination therapy boosts antitumor immunity in BCa

We next examined whether combination therapy could activate adaptive immune responses. We analyzed the percentage of tumor-infiltrating CD8+ T cells by flow cytometry and found that tumor-infiltrating CD8+ T cells were increased by BCG and/or anti-PD-L1 treatment (Figure 4A). Interestingly, BCG and anti-PD-L1 combination therapy induced the greatest increase in tumor-infiltrating CD8+ T cells, as compared to single treatments or the control group. In parallel, significant increases in the percentage of CD8+ T cells producing granzyme B, IFN-γ and TNF-α were also observed in the combination treatment group compared to single treatments or the control group, indicating that BCG and anti-PD-L1 combination treatment not only elevated the number of tumor-infiltrating CD8+ T cells, but also strengthened their antitumor activity (Figure 4B and 4C). In addition, serum IFN-γ level was also further elevated in the combination treatment group, demonstrating that BCG and anti-PD-L1 combination therapy significantly strengthened immune response in BCa (Figure 4D).

MDSCs in the tumor microenvironment can suppress immune responses and facilitate tumor relapse. To determine the dynamics of MDSCs accumulation in the tumor microenvironment, we sought to investigate possible changes in the percentage of MDSCs following treatment. We observed that MDSCs, defined by CD45+CD11b+Gr1+ expression, were reduced by BCG and/or anti-PD-L1 treatment. In tumors that received BCG or anti-PD-L1 treatment alone, the percentage of MDSCs decreased from 12.04±1.03% in untreated

![Figure 3](image_url)  
**Figure 3** BCG and anti-PD-L1 combination therapy inhibited tumor progression and prolonged survival in the orthotopic rat BCa model.  
**Notes:** (A) Study design: orthotopic rat BCa models received intravesical BCG instillation (500 μg) every week for four doses and/or 200 μg anti-PD-L1 (clone 10F.9G2) or isotype control i.p. every 4 days for a total of seven times (n=10 animals per group). Tumor weight (B) and survival percentage (C) were monitored and measured at the endpoint (animal death date or day 60). *P<0.01; **P<0.05.  
**Abbreviations:** BCG, Bacillus Calmette–Guérin; i.p., intraperitoneal injection; PD-L1, programmed death-ligand 1.
Figure 4 BCG and anti-PD-L1 combination therapy elevated the number and activity of tumor-infiltrating CD8+ T cells in the orthotopic rat BCa model.

Notes: (A) Left panel: representative histograms obtained by flow cytometry showing the fluorescence intensity of CD8+ T cells. Right panel: quantitative data of tumor-infiltrating CD8+ T cells from different groups is shown. (B) Left panel: representative images showing immunostaining for granzyme B (brown staining) in tumors from different groups. Right panel: quantification of the percentage of granzyme B positive cells on tumor sections. (C) Representative data showed the percentage of CD8+ T cells producing granzyme B, IFN-γ and TNF-α from different groups by flow cytometry. (D) Serum IFN-γ level from different groups, given by ELISA assay. *P<0.001; **P<0.01.

Abbreviations: BCa, bladder cancer; BCG, Bacillus Calmette–Guérin; ELISA, enzyme linked immunosorbent assay; FITC, fluorescein isothiocyanate; PD-L1, programmed death-ligand 1.
Bcg and anti-PD-L1 combination therapy in BCa

FL1 log (FITC-CD11b+)/ FL2 log (PE-Gr1+)

Control group

10^4 10^5 10^6
N1 N2 N3 N4

BCG group

10^4 10^5 10^6
N1 N2 N3 N4

Anti-PD-L1 group

10^4 10^5 10^6
N1 N2 N3 N4

Combination group

10^4 10^5 10^6
N1 N2 N3 N4

Figure 5 BCG and anti-PD-L1 combination therapy reduced the number of MDSCs in the orthotopic rat BCa model.

Notes: Left panel: representative dot plots obtained by flow cytometry showing the fluorescence intensity of MDSCs. Right panel: quantitative data of the percentage of MDSCs from different groups is shown. * P < 0.001; ** P < 0.05; *** P < 0.01.

Abbreviations: BCa, bladder cancer; BCG, Bacillus Calmette–Guérin; FITC, fluorescein isothiocyanate; MDSCs, myeloid-derived suppressor cells; PD-L1, programmed death-ligand 1; PE, phycoerythrin.

tumors to 5.96% ± 0.88% and 7.09% ± 0.97%, respectively. Combination treatment of BCG and anti-PD-L1 exhibited the greatest effect on MDSCs and further reduced the percentage to 2.65% ± 0.55% (Figure 5). Our results indicated that BCG and anti-PD-L1 combination therapy successfully boosted host antitumor immunity, not only by enhancing T cell immune response but also by reducing the accumulation of MDSCs in the tumor microenvironment.

Discussion

Current studies indicate that immune resistance factors play important roles in the mechanism of BCG failure, which is one of major obstacles in the treatment of NMIBC. PD-L1, as a vital inhibitory checkpoint molecule, has gained increasing attention in tumor immunity. PD-L1 expression on tumor cells has been linked to a weakened host immune response, consequent poor prognosis and resistance to anti-cancer therapies in various malignancies, including lung, breast, gastric, colorectal, ovarian, and renal cancers, and BCa. 7–10 Although previous studies have pointed out the possibility that BCG treatment may lead to the upregulation of PD-L1 expression as well as inducing a strong local inflammatory response, up to now little is known about the detailed relationship between PD-L1 expression and BCG immunotherapy in BCa, which needs to be clarified.

In the present study, we investigated the effect of BCG treatment on PD-L1 expression in BCa cells and also evaluated the efficacy of BCG and anti-PD-L1 combination therapy in immunocompetent orthotopic rat BCa models. We confirmed that PD-L1 expression was obviously upregulated in BCa cells in response to BCG treatment both in vitro and in vivo. Furthermore, we demonstrated that BCG and anti-PD-L1 combination therapy exerted an enhanced antitumor effect on orthotopic rat BCa models by reducing tumor burden and prolonging survival. The antitumor immunity also got a boost with an obvious increase in the number and activity of tumor-infiltrating CD8+ T cells, as well as suppression of MDSCs in the tumor microenvironment.

The relationship between PD-L1 expression and BCG induction in the inflammatory immune response has been
It has been shown that MDSCs have a close relationship with PD-L1/PD-1 axis and BCG immunotherapy.\textsuperscript{23,24} It has been demonstrated that MDSCs could upregulate PD-1 expression in CD8\(^+\) T cells and induce activated T cell exhaustion,\textsuperscript{23} and in addition, recent studies indicated that CD8\(^+\) T cell-to-MDSC balance was associated with the recurrence of BCa undergoing BCG immunotherapy.\textsuperscript{24} Patients with a low CD8\(^+\) T cell/MDSC ratio showed high recurrence rate after intravesical BCG immunotherapy. In our study we found that MDSCs in tumor tissues were reduced by BCG or anti-PD-L1 therapy, while the combination therapy exhibited the greatest inhibitory effect. Previous studies have demonstrated that activated CD8\(^+\) T cells could induce an increase in MDSCs apoptosis in a TNF-\(\alpha\)-dependent manner.\textsuperscript{25} Indeed, we also found the expression of TNF-\(\alpha\) on CD8\(^+\) T cells was significantly increased in the tumors treated with combination therapy. Thus, we speculate that our combination therapy could enhance cytotoxic T cell functions, which, in turn, negatively regulate the accumulation of MDSCs. Further studies are still needed to clarify the precise mechanisms of MDSCs downregulation with BCG and anti-PD-L1 combination therapy.

Several ongoing clinical trials are investigating the rational combination of BCG therapy with PD-L1/PD-1 blockade. NCT02792192 is a Phase Ib/II clinical study assessing combination atezolizumab (anti-PD-L1 antibody) with BCG therapy for high-risk NMIBC. NCT02324582 and NCT02808143 are both Phase I clinical studies assessing pembrolizumab (anti-PD-1 antibody) with BCG therapy for high-risk or BCG-refractory NMIBC. Our findings may provide a preliminary theoretical basis and support for these clinical trials, which will provide more implications on the efficacy and tolerability of the combination therapy and, hopefully, better outcomes for patients with BCa.

There are several limitations to the present study. First, our study is limited to one kind of BCa cell and animal model. The sample size of the animal model is relatively small. Second, our study mainly focused on CD8\(^+\) T cells and MDSCs in the immune response with combination therapy, while some other immune cell subsets, such as CD4\(^+\) T cells, NK cells, neutrophils, monocytes and Tregs, may also play roles in this process. Thus, more tumor cell lines, animal models and involved immune cells are warranted to verify our findings in further studies. In addition, precise mechanisms such as PD-L1 upregulation by BCG and the synergy effect between BCG and anti-PD-L1 therapy need to be well studied in the future.

In conclusion, this is the first study demonstrating that BCG treatment can induce increased expression of PD-L1 in BCa cells. BCG and anti-PD-L1 combination therapy can boost immune response by stimulating CD8\(^+\) T cell activity and suppressing MDSCs, and eventually elicit a potent antitumor effect against BCa. Our results suggest that BCG and anti-PD-L1 combination therapy may be a promising therapeutic strategy for the treatment of BCa patients.
Acknowledgments
This work was supported by National Natural Science Foundation of China (81101932); Science and Technology Project of Qingdao (15-9-1-105-jch); and Higher Educational Science and Technology Program of Shandong (J16LL04).

Disclosure
The authors report no conflicts of interest in this work.

References